1 in 8 Adults Currently Report Taking a GLP-1 Drug for Weight Loss, Diabetes or Other Condition, Even as Half Say the Drugs Are Difficult to Afford

About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds. Few adults think it is likely their prescription costs will go down as a result of recently announced Trump administration policies. Read the news release →  

Medicaid Budget Survey

ACA Resources

8 Things to Watch for the 2026 ACA Open Enrollment Period

The ACA Marketplace Open Enrollment season began November 1, and with it comes looming changes to the enhanced premium tax credits, increases in out-of-pocket premium payments, new Marketplace eligibility rules, and more. Read our analysis of what these and other changes could mean for new and returning enrollees.

Calculator: ACA Enhanced Premium Tax Credit

The ACA’s enhanced premium tax credits are set to expire at the end of 2025. This calculator estimates how much out-of-pocket premiums would increase for families if Congress does not extend the credits. The projected premium increases are estimated based on family income, zip code, size, ages, and 2026 ACA Marketplace premiums.

Medicare Open Enrollment

New and Noteworthy

2025 Employer Health Benefits Survey

This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, worker contributions, cost-sharing provisions, offer rates, and more. This year’s report also looks at how employers are approaching coverage of GLP-1 drugs for weight loss, including their concerns about utilization and cost.

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here